Also in May, phase I researchers reported at ASCO with abemaciclib in patients with advanced KRAS-mutated NSCLC, which showed single-agent activity. NSCLC patients with KRAS mutations, which are common, do poorly, but preclinical studies with the drug indicated that animal models with the mutation showed greater sensitivity to the drug. Phase I enrolled 57 patients with pretreated advanced disease, 29 with KRAS mutations, and 24 with wildtype KRAS. Those taking the CDK4/6 inhibitor demonstrated a 49% control rate; 55% of patients with the KRAS mutation responded, compared with 38% of patients with wild-type KRAS.
T
he rare genetic disease fibrodysplasia ossificans progressiva (FOP) turns a child's muscle tissue into bone, forming a second skeleton that is eventually fatal. Frederick Kaplan, M.D., a leading FOP researcher at the University of Pennsylvania's Perelman School of Medicine, helped identify the mutation responsible and searched for inhibitors. Eight years later, he learned about a bizarre coincidence: Four research teams independently found the same mutation in a rare, inoperable, and incurable pediatric brainstem tumor called diffuse intrinsic pontine glioma (DIPG).
The mutated gene, ACVR1 (also called ALK2), has no previous association with cancer. Researchers found this gene in almost 25% of DIPGs but in no other brain tumors. Despite having the mutation in every cell, FOP patients do not get DIPG.
ACVR1 encodes a cell surface receptor for bone morphogenetic proteins (BMPs).
"We were especially excited because that's a druggable target, and we can benefit from the work on an inhibitor [LDN-193189] already under way in the FOP field," said Chris Jones, Ph.D., a DIPG researcher at the Institute of Cancer Research in London, who led one of four studies in Nature Genetics (Nat. Genet. 2014; 46:457-61) .
"All of a sudden, we have an explosion of insight that occurs when the cancer world and the developmental world meet," Kaplan said. "There's nothing worse than horrible diseases that affect children, and here are two horrible childhood diseases linked by a connection to the same mutation. We now have the best scientists in the pediatric cancer field consulting with scientists in the FOP field to gain insights into mechanisms and treatments that will help children with both diseases."
Blackest of Black Holes
Each year, about 200-300 U.S. children with a median age of 6-7 years are diagnosed with DIPG. DIPGs belong to a group of pediatric high-grade gliomas (HGGs) that look identical to glioblastoma. Traditionally, biopsies are not performed, since results would not change therapy, which for lack of better understanding is based on adult gliomas. Of all the dismal pediatric outcomes for HGGs, DIPGs have the most devastating.
"Median survival for the kids is 9 months. Everyone is dead within 2 years," said Mark Kieran, M.D., Ph.D., of Boston's Dana-Farber Cancer Institute, a coinvestigator of one of the studies (Nat. Genet. 2014; 46:451-6 2012;124:439-47, respectively) . Histone proteins package DNA in tight spools of chromatin, with a "tail" that helps determine whether genes should be accessed by activating transcription factors. The effects are epigenetic because they modify gene activity without changing DNA.
An Epigenetic Partner
In that previous work, researchers identified a new mutation in histone protein H3, called p.Lys27Met, or K27→M. Methionine replaces lysine at position 27 in the protein.
Adding nuance, two H3 mutations, H3.1 and H3.3, cause the same substitution, but H3.3 occurred mostly in the brainstem/ DIPGs. The H3 discovery was unexpected, Baker said, and served as the first clue that DIPGs have a distinct biology.
The new studies found the H3 mutation in almost 90% of DIPGs and analyzed how the two variants associated with different mutations. The researchers identified H3.3 mutation in 60% of DIPGs. The less common H3.1 occurred almost exclusively in DIPG. After H3, the most common mutation in DIPG was ACVR1 (at almost 25%), which almost always occurred with the H3.1 variant.
"We don't really know what's happening at the K27→M substitution," Jabado said. "We think it's losing a repressive mark."
That loss could make a cadre of genes accessible, possibly including ACVR1. Indeed, Hawkins found that expressing ACVR1 and the histone H3 mutation together had an additive effect on the downstream BMP pathway, suggesting cooperation.
Histone H3 is not yet targetable with drugs, but in these studies it often occurred with mutations that might be. In addition to ACVR1, those included PDGFRA (which was mutually exclusive to ACVR1 in DIPG), FGFR1 (in the thalamus), and NTRK (in 40% of infant HGGs outside the brainstem, which were less aggressive)-all genes involved in the developmental PI3K pathway, often dysregulated in cancer.
Emerging Story
Now the cancer and FOP communities can only speculate about how the same ACVR1 mutation may connect both wildly different diseases. The working hypothesis is that in FOP, the germline mutation allows cells in muscle tissue to dedifferentiate and activate a different developmental pathway that tells the cells to redifferentiate as bone cells.
"Dedifferentiation is also a hallmark of cancer, because it allows cells to reactivate a developmental program where they are allowed to divide again," said Kieran. "In FOP, cells dedifferentiate so they can turn on a different fate program. In tumors, they dedifferentiate so they can turn on a different proliferative program." "Interaction between epigenetic dysregulation in pediatric tumors and the ACVR1 mutation is context dependent. It needs to happen in a certain place, a certain cell type, and a certain time in development," Resnick said.
That finding, Kuttesch added, "converges with what we've seen in other childhood cancers."
